Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "eisai"

Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant
Sys-Con Media

Eisai and Purdue Pharma Enter Worldwide Collaboration to Devel...

_ WOODCLIFF LAKE, N.J. Under the terms of the agreement, Eisai and Purdue Pharma will share the costs of lemborexant global clinical studies. While the potential indication for the product candidate is for the treatment of insomnia, the companies ... Sys-Con Media, 10 hours ago
[x]  

39 images for eisai

BioSpace, 1 week ago
Pharma Letter, 1 week ago
WKRB News, 1 week ago
KXXV-TV, 9 hours ago
Sys-Con Media, 10 hours ago
American Banking News, 1 week ago
Pharma Letter, 6 days ago
Pharma Letter, 2 weeks ago
Pharmaceutical Business Review, 1 month ago
Ticker Report, 1 month ago

‘Vizag needs premier pharma research institute’

Eisai Pharma MD calls for sops to sector in AP
 Business Line1 week ago
SearchBug

FYCOMPA® (perampanel) CIII Demonstrates a Significant Reduction in Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency in Phase 3 Trial of Patients with Epilepsy Age 12 and Older

WOODCLIFF LAKE, N.J. , Aug. 24, 2015 /PRNewswire/ -- Eisai Inc. announced today that the results of its Phase 3 trial (Study 332) for FYCOMPA ® (perampanel) CIII have been published in the online edition of Neurology , the medical journal of the ...
 SearchBug1 week ago Eisai Company Release: FYCOMPA (perampanel) CIII Demonstrates A Significant Reduction In Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency In Phase 3 Trial Of Patients With Epilepsy Age 12 And Older  BioSpace1 week ago FDA Grants Breakthrough Therapy Designation to LENVIMA for the Potential Treatment of Metastatic Renal Cell Carcinoma  CancerConnect.com4 weeks ago Eisai seeks Japanese, US & EU regulatory nods for anticancer agent, Halaven to treat soft tissue sarcoma  PharmaBiz1 month ago
[x]  

Eisai reicht in den USA, Japan und der EU einen Antrag für eine neue Indikation für Halaven® (Eribulin) bei Weichteilsarkomen ein

/PRNewswire/ -- NUR FÜR MEDIEN AUS EMEA-LÄNDERN. NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ//ÖSTERREICH/DEN USA JOURNALISTEN Eine Typ 2 Variation zur Beantragung der Erweiterung der Indikation von Halaven ® (Eribulin) wurde in der ...
 PR Newswire1 month ago

Halaven® (éribuline) : Eisai dépose des demandes d'enregistrement simultanément aux Etats Unis, au Japon et UE pour le traitement du sarcome des tissus mous

/PRNewswire/ -- Une demande de variation de type II a ete soumise en union europeenne, pour l'extension d'indication d' Halaven ® (eribulin) dans le traitement des patients atteints de sarcome des tissus mous, non resecable ayant recu au ...
 PR Newswire1 month ago

Eisai presenterà la richiesta di autorizzazione all'immissione in commercio di Halaven® (Eribulina) per il sarcoma dei tessuti molli negli Stati Uniti e in Giappone

/PRNewswire/ -- DESTINATO ESCLUSIVAMENTE AI MEDIA DELL'AREA EMEA: NON DESTINATO AI GIORNALISTI DI SVIZZERA/ AUSTRIA /STATI UNITI In data odierna verrà presentata la richiesta di autorizzazione all'immissione in commercio nell'Unione europea ...
 PR Newswire1 month ago

Eisai solicita autorización en la Unión Europea, Estados Unidos y Japón para una nueva indicación de Halaven® (eribulina) en sarcoma de tejidos blandos

/PRNewswire/ -- SOLO PARA LOS MEDIOS DE LA REGIÓN EMEA: NO PARA LOS MEDIOS SUIZOS/AUSTRÍACOS/ESTADOUNIDENSES Se ha presentado una variación de tipo II ante la Unión Europea para ampliar la indicación de Halaven ® (eribulina) al ...
 PR Newswire1 month ago
Pharmaceutical Business Review

JCR Pharmaceuticals and Eisai sign feasibility study agreement

JCR Pharmaceuticals Co., Ltd., a biopharmaceutical company, and Eisai Co., Ltd. have signed a feasibility study agreement, under which they will examine the possibility of applying JCR's proprietary blood-brain-barrier, or BBB, penetration ...
 Individual.com1 month ago Eisai, JCR to discover new CNS treatments using BBB penetration technology  Pharmaceutical Business Review1 month ago JCR and Eisai conclude feasibility study agreement on application of blood-brain-barrier penetration technology to discover new treatments  PipelineReview1 month ago JCR, Eisai conclude feasibility study pact on application of blood-brain-barrier penetration technology to discover new treatments  PharmaBiz1 month ago

Eisai Says New Cancer Drug Reaching Patients Faster Than Planned

Eisai Co. said its new thyroid cancer drug is reaching patients faster than originally planned, months after regulators in its two biggest markets approved the treatment. More patients than had been initially targeted are receiving Lenvima at ...
 Bloomberg1 month ago

Nikkei rises on earnings optimism; Nidec jumps on quarterly results

* Nidec jumps 10 pct on strong April-June results * Eisai tanks after Biogen drug data disappoints * Komatsu, Hitachi Construction Machinery fall before Caterpillar's earnings By Ayai Tomisawa TOKYO, July 23 Japan's Nikkei share ...
 Reuters1 month ago REUTERS - Nikkei rises on earnings optimism; Nidec jumps on quarterly results  Namibia Press Agency1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less